We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$17.5B
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter
Est. Return
+6.32%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$16.2B
AUM Growth
+$1.75B
(+12%)
Cap. Flow
+$1.1B
Cap. Flow
% of AUM
6.8%
Top 10 Holdings %
Top 10 Hldgs %
54.17%
Holding
115
New
28
Increased
36
Reduced
22
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AABA
Altaba Inc
AABA
|
+$784M |
| 2 |
ESRX
Express Scripts Holding Company
ESRX
|
+$504M |
| 3 |
General Dynamics
GD
|
+$348M |
| 4 |
XL
XL Group Ltd.
XL
|
+$329M |
| 5 |
Keurig Dr Pepper
KDP
|
+$194M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$618M |
| 2 |
MON
Monsanto Co
MON
|
+$543M |
| 3 |
COL
Rockwell Collins
COL
|
+$151M |
| 4 |
ABLX
Ablynx NV
ABLX
|
+$134M |
| 5 |
PPLI
People Inc
PPLI
|
+$112M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.63% |
| 2 | Technology | 19.02% |
| 3 | Financials | 14.39% |
| 4 | Communication Services | 11.46% |
| 5 | Industrials | 6.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Arcus Biosciences
RCUS
$3.58B
| – | – |
-11,422
| Closed | -$176K |
|
102
Tronox
TROX
$922M
| – | – |
-688,006
| Closed | -$12.7M |
|
103
VICI Properties
VICI
$29.3B
| – | – |
-337,049
| Closed | -$6.07M |
|
104
Xencor
XNCR
$1.5B
| – | – |
-149,900
| Closed | -$4.49M |
|
105
XPO
XPO
$23.6B
| – | – |
-1,373,412
| Closed | -$48.4M |
|
|
CBAY
106
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-550,000
| Closed | -$7.14M |
|
|
BOLD
107
DELISTED
Audentes Therapeutics, Inc
BOLD
| – | – |
-320,000
| Closed | -$9.62M |
|
|
AHL
108
DELISTED
ASPEN Insurance Holding Limited
AHL
| – | – |
-194,341
| Closed | -$8.72M |
|
|
TWX
109
DELISTED
Time Warner Inc
TWX
| – | – |
-1,020,000
| Closed | -$96.5M |
|
|
ABLX
110
DELISTED
Ablynx NV
ABLX
| – | – |
-2,450,000
| Closed | -$134M |
|
|
MON
111
CALL
DELISTED
Monsanto Co
MON
| – | – |
-2,000,000
| Closed | -$233M |
|
|
MON
112
DELISTED
Monsanto Co
MON
| – | – |
-4,650,000
| Closed | -$543M |
|
|
AVXS
113
DELISTED
AveXis, Inc. Common Stock
AVXS
| – | – |
-294,000
| Closed | -$36.3M |
|
|
CBI
114
DELISTED
Chicago Bridge & Iron Nv
CBI
| – | – |
-660,000
| Closed | -$9.5M |
|
Similar funds
BBA
MCM
LA
CM
ASRS
PP
VMPIC
HNB
Farallon Capital Management's Q2 2018 Portfolio in Review
As of Q2 2018, Farallon Capital Management held 115 positions worth $16.2B, up 12% from $14.4B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Farallon Capital Management deployed $1.1B of net new capital in Q2 2018, opening 28 new positions and adding to 36 existing holdings. Its largest new stake was General Dynamics: 1,697,715 shares worth $316M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was NXP Semiconductors, an estimated $618M trimmed.
- Farallon Capital Management's largest Q2 2018 buy was General Dynamics: 1,697,715 shares worth $316M.
- Farallon Capital Management added most to Altaba Inc in Q2 2018, an estimated $784M increase.
- Farallon Capital Management's biggest Q2 2018 reduction was NXP Semiconductors, cutting an estimated $618M.
- Farallon Capital Management fully exited Monsanto Co in Q2 2018, selling an estimated $543M.
- Farallon Capital Management's ten largest holdings make up 54% of its $16.2B portfolio in Q2 2018.
- Farallon Capital Management opened 28 new positions and closed 20 in Q2 2018.
- Farallon Capital Management's portfolio value rose 12% quarter-over-quarter to $16.2B.
Based on Farallon Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.